Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease

The B7601011 study has a randomized, double-blind, placebo-controlled parallel group design.
Approximately 88 subjects will be randomized to 2 treatment groups. Each subject will
participate in the study for approximately 23 weeks including a 30 day screening period, 15
week double blind treatment period, and an approximately 28 day follow-up period.

Inclusion Criteria:

- Females of non-childbearing potential and/or male subjects

- Clinical diagnosis of Parkinson's disease.

- Parkinson's Disease Hoehn & Yahr Stage I-III inclusive

- Treatment naïve or history of prior incidental treatment with dopaminergic agents for
no more than 28 days

- Able to refrain from any Parkinson's disease medication not permitted by the protocol.

Exclusion Criteria:

- History or presence of atypical Parkinsonian syndrome.

- Severe acute or chronic medical or psychiatric condition or cognitive impairment or
laboratory abnormality.

- Any condition possibly affecting drug absorption.

- Participation in other studies involving investigational drug(s), or treatment with
any investigational drug within 30 days.